News | April 28, 2023
Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Fully equipped labs with 75-member team set-up and made operational in <100 days
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
Calibre will enhance the pace of new product development and the breadth of its Custom Development and Manufacturing (CDMO) Service offerings.
To enable company to be future-ready by tapping potential in CDMO space
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Subscribe To Our Newsletter & Stay Updated
